Education
About Us
Working with TipRanks
Follow Us
BCUS - ETF AI Analysis
Top Page
Bancreek U.S. Large Cap ETF (BCUS)
Rating:73Outperform
Price Target:―
Positive Factors
Strong Leading Holdings
Several of the largest positions, such as Curtiss-Wright, Amphenol, and WW Grainger, have shown strong gains, helping support the ETF’s overall performance.
Broad Sector Mix
The fund spreads its investments across multiple sectors, including industrials, technology, financials, health care, and consumer stocks, which helps reduce reliance on any single industry.
Positive Recent Performance
The ETF has delivered steady gains over the past month, three months, and year-to-date, indicating generally favorable recent results for investors.
Negative Factors
High Industrial Sector Concentration
Nearly one-third of the portfolio is in industrial companies, so a downturn in this sector could have an outsized impact on the fund.
Mixed Results Among Top Holdings
Some major positions like Trane Technologies, CRH, AbbVie, and JPMorgan have shown weak or negative performance, which can drag on the ETF’s returns.
Relatively High Expense Ratio
The fund’s expense ratio is on the higher side for a large-cap U.S. ETF, meaning more of the investment return is used to cover fees.
BCUS vs. SPDR S&P 500 ETF (SPY)
AUM100.34M
RegionNorth America
Expense Ratio0.70%
Beta0.90
IssuerBancreek
Inception DateDec 21, 2023
Dividend Yield0.47%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume4,693
30 Day Avg. Volume6,514
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
38.63Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering30
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BCUS Summary
The Bancreek U.S. Large Cap ETF (BCUS) is an exchange-traded fund that invests mainly in large, well-established U.S. companies, without tracking a specific index. It focuses on big businesses across many sectors, including industrials, technology, finance, and health care. Well-known holdings include JPMorgan Chase and AbbVie. Someone might invest in BCUS to get broad diversification in leading U.S. companies and seek long-term growth with the relative stability that large firms can offer. However, the fund can still go up and down with the overall stock market, so your investment value may fluctuate.
How much will it cost me?The Bancreek U.S. Large Cap ETF (BCUS) has an expense ratio of 0.7%, which means you’ll pay $7 per year for every $1,000 invested. This is higher than average because the fund is actively managed, requiring more resources to select and monitor investments compared to passively managed ETFs that track an index.
What would affect this ETF?The Bancreek U.S. Large Cap ETF (BCUS) could benefit from positive trends in the U.S. economy, such as technological innovation and industrial growth, which align with its significant exposure to the Technology and Industrials sectors. However, rising interest rates or economic slowdowns could negatively impact consumer spending and financial sector performance, which are also key components of the fund. Regulatory changes or geopolitical tensions affecting large-cap companies may further influence the ETF's future performance.
BCUS Top 10 Holdings
BCUS leans heavily into U.S. industrial powerhouses, with names like Curtiss-Wright, Parker Hannifin, and WW Grainger doing much of the heavy lifting as their shares keep rising on solid earnings and upbeat outlooks. Tech supplier Amphenol is another quiet engine of growth, adding a steady tailwind. On the flip side, AbbVie and JPMorgan are losing steam, while Trane Technologies and CRH show more mixed, stop‑and‑go trading. Overall, this is a U.S.-centric fund driven by industrial strength, with health care and financials acting as the main speed bumps.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| InterDigital | 4.30% | $4.31M | $9.53B | 81.39% | 76 Outperform | |
| Amphenol | 4.26% | $4.27M | $166.75B | 106.15% | 78 Outperform | |
| Cardinal Health | 4.09% | $4.10M | $53.26B | 75.84% | 66 Neutral | |
| CRH plc | 4.04% | $4.04M | £62.16B | 12.88% | 76 Outperform | |
| Trane Technologies | 4.02% | $4.02M | $100.65B | 27.56% | 70 Outperform | |
| Transdigm Group | 3.99% | $3.99M | $72.60B | -4.50% | 69 Neutral | |
| Parker Hannifin | 3.94% | $3.94M | $123.25B | 43.74% | 79 Outperform | |
| Casey's General | 3.88% | $3.88M | $24.50B | 54.12% | 68 Neutral | |
| JPMorgan Chase | 3.85% | $3.86M | $877.66B | 17.13% | 72 Outperform | |
| Boston Scientific | 3.78% | $3.78M | $113.11B | -30.06% | 79 Outperform |
BCUS Technical Analysis
Positive
―
Price Trends
32.63
Positive
32.46
Positive
31.89
Positive
Market Momentum
0.14
Negative
60.12
Neutral
65.05
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BCUS, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 33.06, equal to the 50-day MA of 32.63, and equal to the 200-day MA of 31.89, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 60.12 is Neutral, neither overbought nor oversold. The STOCH value of 65.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BCUS.
BCUS Peer Comparison
Comparison Results
Performance Comparison
BCUS
Bancreek U.S. Large Cap ETF
33.68
2.99
9.74%
LVDS
JPMorgan Fundamental Data Science Large Value ETF
―
―
―
UPSD
Aptus Large Cap Upside ETF
―
―
―
ACEP
ARS Core Equity Portfolio ETF
―
―
―
EGGY
NestYield Dynamic Income Shield ETF
―
―
―
HUSV
First Trust Horizon Managed Volatility Domestic ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents